SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
SkyePharma PLC
By: /s/ Douglas Parkhill
Name: Douglas Parkhill
Title: Company Secretary
Date: 19 April, 2006
FOR IMMEDIATE RELEASE 19 APRIL 2006
SkyePharma PLC
Preliminary Results Announcement
for the year ended 31 December 2005
LONDON, UK, April 19, 2006 - SkyePharma PLC (LSE: SKP; Nasdaq: SKYE) announces
the Company's preliminary results for the year ended December 31, 2005.
Operating highlights
• Paxil CRTM back on US market
• TriglideTM launched in USA
• Pulmicort HFA-MDI filed
• Foradil Certihaler™ now approved in more than 20 markets
• FlutiformTM starts Phase III clinical trials
• DepoBupivacaineTM completes Phase II clinical trials
• FlutiformTM licence negotiations ongoing with several parties
• DepoBupivacaineTM licensed to Mundipharma and Maruho
• Rights issue raised 35 million (net of expenses)
• Strategic decision to divest injectables business unit
Financial highlights (under IFRS)
• Turnover down by 18% to 61.3 m (2004: 75.2 m)
• Absence of FlutiformTM licensing revenues
• Strategic shift from up fronts to royalties
• Royalty income decreased by 16% to 21.7 m (2004: 25.9 m)
• Paxil CRTM supply problems
• Royalties excluding Paxil CRTM up 38%
• Gross profit down 32% to 32.1 m (2004: 47.0 m)
• Exceptional items of 21.4 m (2004: 8.9 m)
• Non cash investment impairments 19.4m
• Abortive transaction costs 2.0m
• Operating loss before exceptionals 16.1 m (2004: 0.4 m)
• Operating loss after exceptionals 37.5 m (2004: 3.1 m)
• Net loss 50.9 m (2004: 18.6 m)
• Loss per share 8.1p (2004: 3.0p)
• End 2005 net cash 34.3 m (2004: 15.3 m)
Dr Jerry Karabelas, Non-executive Chairman, said: "2005 was a difficult year for
SkyePharma but the Company now has a new management team and has adopted a new
strategy. We are focused in the short term on the licensing of Flutiform™ and
the divestment of our injectables business. While there is obviously uncertainty
as to the timing of these two transactions, they will not only greatly reduce
the Company's current and future cash requirements but also provide us with the
funds to consider new opportunities related to oral and inhalation products. We
remain convinced that Flutiform™ will become a major product. We believe that
the strategic initiatives we have adopted will enable the Company to maximise
the potential of Flutiform™ and other pipeline products, to become profitable in
the near term and to deliver long-term value for shareholders."
For further information please contact:
SkyePharma PLC
Jerry Karabelas, Non-executive Chairman
Frank Condella, Chief Executive Officer
Peter Laing, Director of Corporate Communications
Today +44 207 466 5000
Thereafter +44 207 491 1777
Sandra Haughton, US Investor Relations +1 212 753 5780
Buchanan Communications +44 207 466 5000
Tim Anderson / Mark Court / Rebecca Skye Dietrich
CHAIRMAN'S STATEMENT
There is no disguising that 2005 was a difficult year for SkyePharma. Despite a
number of significant achievements, outlined in the Review of Operations below,
we did not complete a development agreement for Flutiform™, our major pipeline
product. We believe that Flutiform™ has substantial commercial value. Faced with
the prospect of a delay to the development of this important product, which
might have impaired its commercial potential, we took the decision in September
to raise 35 million (net of expenses) by means of a rights issue to keep
Flutiform™ on its planned development timeline through Phase III. As such, our
target launch date in the USA remains 2009. We are convinced that the decisions
to proceed with the clinical development of Flutiform™ ourselves and to fund
this development through a rights issue were in shareholders' best interests.
We continue to have negotiations with potential strategic marketing partners for
Flutiform™ who could also fund development of additional indications following
initial approval for asthma. We hope to finalise an agreement with one or more
marketing partners for FlutiformTM as soon as reasonably possible. The Board
remains confident that an agreement will be reached in 2006.
Prior to reaching the decision to ask shareholders for funding, we explored a
number of financing alternatives to fund the development of Flutiform™ and also
a variety of strategic options for the Company. These included discussions
concerning a transaction that, had it been successful, would have created a
combined company that could have marketed Flutiform™ itself in some markets. The
discussions were called off by SkyePharma due to uncertainties over the other
party's prospects. SkyePharma was unable to disclose this at the time due to
reasons of confidentiality and the possibility that these discussions could
resume at some time in the future.
In November, we also received an opportunistic takeover approach from Innovata
PLC. As a result, the Board felt that it was in shareholders' interests to
explore all options and consequently appointed Lehman Brothers to conduct a full
strategic review of all the options open to the Company.
The conclusion of this review in early 2006 did not lead to an offer for the
entire Company on terms that the Board felt able to recommend to shareholders.
However, there were expressions of interest in individual parts of the business.
The Board then took a strategic decision to divest the US-based injectables
business in order to reduce the Company's projected cash outflow over the next
few years and to raise funds to concentrate on the oral and inhalation
businesses. The investment bank UBS has been retained recently to manage this
sale and the process is ongoing. The injectables business includes DepoCyt™ and
DepoDur™, both marketed products, and the lead injectable pipeline product
DepoBupivacaine™.
In January 2006 certain shareholders requisitioned an Extraordinary General
Meeting ("EGM") seeking to remove the Company's then Chairman and to appoint a
nominated director to SkyePharma's Board with the ultimate aim of having him
appointed as Executive Chairman. Although this motion was defeated at the EGM in
early March, the Board has since made a number of changes and introduced a
process whereby major investors are now involved in the selection of new
Non-Executive Directors.
Board Changes
In January 2006, Ian Gowrie-Smith stepped down from his role as Non-Executive
Chairman when I was appointed in his place. Ian subsequently resigned as a
Director in February. As shareholders will be aware, Ian founded SkyePharma in
1996 and has seen it grow to become a substantial business. He remains a
shareholder but will now be focusing his energies on a number of early-stage
non-pharmaceutical companies. I have been a Non-Executive Director of SkyePharma
since 2000 and I have also had extensive experience at senior management levels
of the international pharmaceutical industry.
Michael Ashton, who has now reached the age of 60, indicated to the Board last
year that it was his intention to retire as Chief Executive in 2006. Michael
will continue to serve as a Director until the 2006 Annual General Meeting in
June but will not be seeking re-election.
I am sure that shareholders will join me in thanking both Ian and Michael for
their contribution to the development of SkyePharma since its formation.
The Board has appointed Frank Condella as Chief Executive, who joined the
Company on 1 March 2006, having previously run the European operations of the
leading generic company IVAX. Before joining IVAX, Frank was Chief Executive of
Faulding Pharmaceuticals and before that built up the speciality pharmaceuticals
business of Roche. Frank joined the Board on 4 April 2006.
The Board has also appointed Dr Ken Cunningham in the new role of Chief
Operating Officer. Ken was formerly Chief Executive of the private UK company
Arakis and has a wealth of experience in pharmaceutical development, especially
in the areas of oral and inhalation products.
Two other Non-Executive Directors, Sir Michael Beavis and Dr Keith Mansford,
will not be standing for re-election at the Annual General meeting. The Board
will miss their wise counsel and wishes them well in retirement. In their place,
we will be appointing two new Non-Executive Directors.
The Future
The EGM process was costly and also diverted significant management time away
from running the business. However, now that this is behind us we can focus on
execution of the new strategy referred to above and outlined in more detail in
the following pages. We are focused in the short term on the licensing of
Flutiform™ and the divestment of our injectables business. While there is
obviously uncertainty as to the timing of these transactions, they will not only
greatly reduce the Company's current and future cash requirements but also
provide us with the funds to consider new opportunities related to oral and
inhalation products. We are also devoting a significant amount of resource to
ensure that Flutiform™ continues on its planned development timeline. We remain
convinced that Flutiform™ will become a major product, as is evident from the
number of companies that have expressed an interest in obtaining licensing
rights. We believe that the strategic initiatives we have adopted will enable
the Company to maximise the potential of Flutiform™ and other pipeline products,
to become profitable in the near term and to deliver long-term value for
shareholders.
Dr Jerry Karabelas
Non-Executive Chairman
STRATEGY
SkyePharma's mission is to become one of the world's leading speciality
pharmaceutical companies, powered through excellence in drug delivery.
On 2 February 2006, the Company announced the outcome of its Strategic Review.
The Board concluded that in the interests of achieving sustainable profitability
in the shortest reasonable time, SkyePharma should concentrate on oral and
inhalation products and divest its injectable business interests. The proposed
divestment, which the Board expects to be subject to approval by shareholders,
would not only release cash but also relieve the Company of a significant cash
burn and future capital expenditure. The Board believes that the residual core
business would be able to achieve profitability in the near term. Furthermore,
with greater focused resources the Company would be in a better position to
further develop its pipeline of oral and inhalation products. Ultimately, it is
the Company's strategy to add a niche sales and marketing capability in one or
more markets that would improve profit growth and give it greater control over
revenue generation.
The injectables business, located in San Diego, consists of two marketed
products: DepoCyt for a complication of cancer and Depodur for the treatment of
post-surgical pain. This business also has a pipeline of projects in various
stages of development. These include controlled-release injectable formulations
of a number of biological products and DepoBupivacaine™, a long-acting
injectable formulation of the local anaesthetic bupivacaine for the control of
post-operative pain. The Company remains convinced that DepoBupivacaine™
addresses an important area of unmet medical need and has major commercial
potential. However, further development of this business would require
significant cash resources and would also impact the Company's ability to become
profitable in the near term.
The Company has retained UBS to act as its investment bank to manage the
divestment process. This process is ongoing and several third parties, both
trade and financial, have already shown significant interest in the injectables
business.
Funds raised by the divestment of the injectables business will be available to
enhance the core oral and inhalation business. We expect to be able to
accelerate the development of certain pipeline products whose development has
had to be delayed in recent years. Several of these products are at an early
stage of development but would address important therapeutic areas such as
gastrointestinal, diabetes and hypertension. Development activities will
continue to be based in Muttenz, Switzerland and manufacturing in Muttenz and
Lyon, France.
Our oral and inhalation pipeline includes SkyePharma's most important project
Flutiform™, a combination asthma product. The Company is convinced that
Flutiform™ has substantial value as it is poised to enter a large and rapidly
growing market with currently limited competition. We are currently negotiating
with several companies for the rights to market Flutiform™ in the US, Canada,
Japan and the countries of the European Union.
The core oral and inhalation business has seven products marketed by licensees,
including Paxil CR™, Xatral OD and Triglide™. These products will continue to
generate revenues and cash for the Company. There are also a number of
late-stage products that are close to the market.
The Company will focus its efforts on working with partners to maximise revenues
from existing and future marketed products. We will also be able to devote more
resources in this area to the development of additional products and to increase
the size of our pipeline.
OPERATIONAL REVIEW
INHALATION PRODUCTS
FlutiformTM HFA-MDI
FlutiformTMHFA-MDI is a fixed-dose combination of the long-acting bronchodilator
formoterol and the inhaled steroid fluticasone in a metered-dose aerosol inhaler
(MDI) using a hydrofluoroalkane (HFA) propellant.
The world market for asthma drugs is expected to exceed $20 billion by 2010,
with use in chronic obstructive pulmonary disease (COPD) expected to add a
further $10 billion. The fastest-growing part of this market is combination
treatments, which combine a long-acting bronchodilator with an inhaled steroid
in a single delivery device. Combinations are not only convenient for patients
but also optimise the efficacy of the individual agents. Sales of
GlaxoSmithKline's combination Advair (Seretide in Europe) already exceed $6
billion and AstraZeneca's Symbicort (which is not yet on the US market) add
another $1 billion. By 2010 the combination category is expected to account for
over half of the asthma/COPD market by value.
Formoterol provides 12 hours of bronchodilation and has a rapid onset of action
(1-3 minutes). By contrast salmeterol, the bronchodilator used in
GlaxoSmithKline's Advair/Seretide, is also a twice-daily product but has the
drawback of needing 30-45 minutes after inhalation to take effect. The inhaled
steroid fluticasone (a component of Advair/Seretide) is perceived to have a
better safety and efficacy profile than budesonide, the steroid used in
AstraZeneca's Symbicort, and is the physician-preferred inhaled steroid in the
US. The SkyePharma formulation technology employed in Flutiform™ provides patent
protection to 2019.
In 2005 the Company completed phase II trials and a review of development
activities with the FDA and European regulatory agencies. Subsequent to these
meetings, the Company initiated Phase III trials for Flutiform™ in February
2006. The product is on track for its target filing date with the US Food and
Drug Administration ("FDA") in the second half of 2007, with US market entry
expected in early 2009. SkyePharma expects Flutiform™ to be the third
combination product to enter the US market, following GlaxoSmithKline's Advair
and AstraZeneca's Symbicort. Despite the eventual likelihood of additional
entrants, the Company believes that no competing product is likely to enter the
US market before 2012. We believe that Flutiform™ will be at worst the third
combination on the US market and differentiated from both Advair and Symbicort.
There is potential to position Flutiform™ as "Best in Class". Furthermore there
is limited risk of generic competition in the combination asthma market because
there is no recognised test for bioequivalence after inhalation dosing and
therefore no basis for approval of an "AB rated" generic inhaled drug in the US
market.
A generic company would therefore have to conduct clinical trials, which is much
more expensive and risky than development of a conventional oral generic drug -
so typical generic deep-discount pricing would not be possible. We therefore
anticipate a peak sales potential for Flutiform™ well in excess of $1 billion
with an appropriate marketing partner.
SkyePharma had previously sought a partner to pay for the clinical development
of Flutiform™ but negotiations have taken longer than expected. In September
2005 we therefore decided to raise funds to proceed with Phase III development
at our own expense. The Phase III trials will cost in excess of $50 million.
This decision kept development under our control and reduced the risk of delays
to market entry that could jeopardise the sales potential of Flutiform™. It is
still our intention to appoint a licensee or licensees as soon as possible.
However, SkyePharma's flexibility on the terms and structure of any licensing
deal has been significantly increased by removal of the partner funding
obligation, elimination of the majority of the development risk and proximity to
launch. SkyePharma remains in discussions with various potential marketing
partners.
Foradil Certihaler™
Foradil Certihaler™ is our version of Novartis' long-acting bronchodilator
Foradil (formoterol). Global sales of Foradil were $332 million in 2005, of
which the Certihaler™ version made up a very small proportion, the product
having only been on the market for a short time. We developed not only the
multi-dose dry-powder inhaler device but also the formulation technology that
had been shown to ensure dose consistency. Foradil Certihaler™ has now been
approved in 22 countries in Europe, the Middle East and Latin America. The
product was launched in Germany and Switzerland in September 2005 but a recall
from these markets was initiated in January 2006 because of concerns that
accidental mishandling of the device had resulted in inaccurate dosing in a
small number of cases. SkyePharma is collaborating with Novartis and the
relevant health authorities to investigate the reasons and the actions necessary
before the product can be returned to the market. These are likely to include
modification of the patient use instructions and the device. In the US, the FDA
issued an "approvable" letter for Foradil Certihaler™ in April 2006. However,
the FDA is requiring device modification as a prerequisite for approval.
Novartis is currently working with the FDA on the most effective way to address
its concerns.
The Certihaler™ and related formulation technology are also involved in a second
collaboration with Novartis to jointly develop QAB149 (indacaterol), a novel
inhaled long-acting beta-2-agonist that provides sustained 24-hour
bronchodilation with rapid onset of action, which has completed Phase II
development in both asthma and COPD. Novartis is currently revising the
indacaterol development plan in Certihaler™ to accommodate the device
modifications mentioned above.
Formoterol HFA-MDI
This is a formulation of the long-acting bronchodilator formoterol in an
HFA-powered MDI. Because of the growing use of combination products for asthma
and COPD, there is now a correspondingly diminishing market opportunity for
single agent bronchodilators. While this product has completed Phase II
development, pending the divestment of the injectables business, the Company
will conclude its strategic review of this product.
Pulmicort HFA-MDI
This new HFA-powered MDI containing AstraZeneca's inhaled corticosteroid
Pulmicort (budesonide) was filed for marketing authorization in June 2005 on a
country-by-country basis in Europe for the treatment of asthma in adults and
children. In February 2006, the product received approval in Finland, its first
European market. Other European approvals are expected this year. The currently
available MDI formulation of Pulmicort has been on the market since 1981 and
uses chlorofluorocarbons (CFCs) as the propellant. In accordance with the
Montreal Protocol, this version will now be replaced by the non-ozone depleting
device using HFAs as propellant. SkyePharma developed this new HFA-MDI
formulation, which employs its proprietary formulation technology, and also
conducted the clinical development programme for AstraZeneca. SkyePharma will
earn a double digit royalty on AstraZeneca's sales of this formulation of
Pulmicort.
ORAL PRODUCTS
Paxil CRTM
Our improved formulation of GlaxoSmithKline's antidepressant Paxil(paroxetine)
remains a major source of royalty income. In March 2005 GlaxoSmithKline
temporarily suspended production of Paxil CRTM and certain other products made
at its Cidra plant in Puerto Rico. GlaxoSmithKline announced in April 2005 that
it had entered into a consent decree with the FDA regarding manufacturing
processes at the plant and recommenced supply of product to the market shortly
thereafter. As previously reported, we concluded a new agreement with
GlaxoSmithKline last year that not only provided us with a $10 million lump-sum
payment and increased the royalty rate on this product from 3% to 4% but also
maintained our royalty income even while the product was temporarily off the
market.
Despite the product's return to the market, new documentary procedures
introduced as part of the consent decree have hindered the Cidra plant's ability
to meet demand and GlaxoSmithKline alerted customers to supply constraints in
January 2006. Paxil CRTM currently holds about 3% of new prescriptions in this
market, well below the 7% share held before the March 2005 withdrawal. World
sales of Paxil CRTM were $231 million in 2005, of which US sales were $209
million, 70% below the 2004 level in constant exchange rate terms.
In late 2005 we and our partner GlaxoSmithKline received notification from Mylan
Pharmaceuticals Inc. that it had filed an Abbreviated New Drug Application
("ANDA") with the FDA for a version of paroxetine hydrochloride extended release
tablets. The ANDA contains a "Paragraph IV certification" that certain of the
patents listed in the FDA's "Orange Book" by GlaxoSmithKline for Paxil CR
(paroxetine hydrochloride Controlled Release tablets) are not infringed. These
patents include SkyePharma's US patent 5,422,123. The certification does not
challenge GlaxoSmithKline's basic active ingredient patent covering paroxetine
hydrochloride hemihydrate, which protects the product until June 2007.
GlaxoSmithKline has decided not to exercise its right to file suit for patent
infringement within the 45-day period permitted by the Hatch-Waxman Act ("the
Act") and therefore there will be no 30-month stay of approval for this product
pursuant to the Act. SkyePharma has a number of issued patents covering
technology incorporated in Paxil CRTM and our policy is to enforce our
intellectual property wherever possible.
Requip Once-a-day
In December 2005, SkyePharma's collaborator GlaxoSmithKline submitted Requip
Once-a-day, a once-daily dosage formulation of Requip(ropinirole), for approval
by US and European regulatory authorities for the treatment of Parkinson's
disease. The FDA has raised some administrative issues that were identified in
the preliminary initial review and which led GlaxoSmithKline to withdraw the US
filing. SkyePharma has been informed that it is the intention of GlaxoSmithKline
to resubmit as soon as possible. It is not expected that the European regulatory
review process will be affected by these issues. This new once-daily oral
formulation of Requip incorporates SkyePharma's Geomatrix™ oral
controlled-release delivery technology. SkyePharma will receive royalties on the
product sales.
Triglide™
Following FDA approval in May 2005, First Horizon Pharmaceutical Corporation
launched Triglide™ (fenofibrate) on the US market in July. First Horizon, which
licensed Triglide™ in 2004, has a 500-strong representative force focused on
cardiovascular physicians and high-prescribing primary care practitioners and
has a proven ability to capture market share in the cardiovascular therapeutic
area. We and First Horizon see a substantial opportunity for Triglide™, a
once-daily oral treatment for lipid disorders such as elevated cholesterol and
triglycerides. Fenofibrate not only lowers levels of total triglycerides and LDL
cholesterol ("bad cholesterol") in the bloodstream but also has the valuable
property of raising abnormally low levels of HDL cholesterol ("good
cholesterol"), increasingly recognized as a major cardiovascular risk factor. In
Triglide™, the problem of variable uptake arising from the low solubility of
fenofibrate has been overcome by our proprietary IDD-P™ solubilization
technology. Triglide™ has comparable absorption under both fed and fasting
conditions and therefore allows patients to take the drug at any time, improving
compliance and simplicity for both patients and prescribers. First Horizon's
2005 sales of Triglide™ in the 5 months since launch were just under $5 million
but we and First Horizon expect a significant increase in the current year.
SkyePharma has now received $20 million in milestone payments from First Horizon
($15 million of which was due on FDA approval, obtained in May 2005) and could
receive up to $30 million more in sales-based milestone payments. In addition we
receive 25% of First Horizon's net sales, out of which we pay for manufacturing
and supply. In 2005 we also agreed to contribute towards the marketing costs
incurred by First Horizon to establish the product in its first two years after
launch, the aim being
to enhance market penetration and thereby optimize revenues. Originally we
agreed to contribute up to $5 million towards First Horizon's marketing costs
through 2007 and to provide samples. In January 2006 this arrangement was
modified in order to emphasise its intent as a marketing contribution.
SkyePharma will now make a contribution of up to $11.3 million towards First
Horizon's marketing costs (of which $3.1 million was paid in 2005) and First
Horizon will pay SkyePharma for the supply of product samples. There is no
change in the net cost to SkyePharma.
Xatral OD
Xatral OD (Uroxatral in the USA) is our once-daily version of Sanofi-Aventis's
Xatral (alfuzosin), a treatment for the urinary symptoms of benign prostatic
hypertrophy. Xatral OD has been on the market outside the USA since April 2000
and the older multidose versions of Xatral have now largely been withdrawn.
Uroxatral, launched in the US in November 2003, currently holds over 11% of the
combined prescriptions written for it and for its principal competitor Flomax
(tamsulosin, jointly marketed in the US by Boehringer Ingelheim and Astellas).
Xatral OD has now been approved in more than 50 countries, including 24 in
Europe, for a second indication, acute urinary retention. However Sanofi-Aventis
is no longer pursuing US approval for this indication. In 2005, global sales of
all forms of Xatral reported by Sanofi-Aventis were €328 million ($410 million),
up by 18% in constant exchange rate terms. Included in this total were US sales
of Uroxatral of €53 million ($66 million), up by 121% in constant exchange rate
terms. We estimate that Xatral OD now accounts for more than 90% of the sales of
Xatral reported by Sanofi-Aventis.
Zyflo CR
SkyePharma's partner Critical Therapeutics, Inc. announced in January 2006 that
it had initiated two studies designed to support a New Drug Application for a
twice-daily version of Zyflo (zileuton), an oral leukotriene synthesis inhibitor
for the treatment of asthma. The current version of Zyflo has to be taken four
times a day and the CR version is expected to improve convenience for patients
and therefore compliance. The controlled release formulation employed in the CR
version was developed by SkyePharma. Critical Therapeutics expects to file the
CR version with the FDA in the third quarter of 2006.
OTHER PRODUCTS
Solaraze
Solaraze is our topical gel treatment for actinic keratosis and our proprietary
hyaluronic acid formulation ensures that a high concentration of the active
ingredient is maintained in the upper layers of the skin. Solaraze is now
marketed in the US by the Doak Dermatologics unit of Bradley Pharmaceuticals.
Bradley has recently reported that sales in the first nine months of 2005 were
just under $10 million and SkyePharma estimates that full year sales were
approximately $15 million. Sales in 2004 were only $6 million, reflecting the
fact that product rights were not acquired by Bradley until August 2004.
Solaraze is marketed in Europe and certain other territories by Shire
Pharmaceuticals. In 2005 Shire's total non-US sales of Solaraze were $12.5
million, up by 32%.
INJECTABLE PRODUCTS (TO BE DIVESTED)
Biologicals portfolio
There has been encouraging progress with the Company's portfolio of versions of
protein drugs with enhanced delivery profiles, based on its two complementary
sustained-release injectable technologies DepoFoam™ and Biosphere™. The
objective of the work has been to develop different protein formulations to
provide a range of durations from 7 up to 28 days of activity. The DepoFoam™
system has the benefit of neither altering the native protein during the
formulation process nor the way in which it acts upon release into the body.
SkyePharma has now successfully formulated seven different protein drugs,
including major commercial products such as G-CSF, EPO, HGH, IFN-a and IFN-. In
the second half of 2005 the Company entered into three new feasibility study
agreements with third parties for enhanced biologics. It is anticipated that
several of these products will enter Phase I clinical trials in 2007.
DepoBupivacaineTM
We are pleased to report that we have now completed the Phase II trial programme
for DepoBupivacaine™, a long-acting local anaesthetic for use in the treatment
of post-operative pain. DepoBupivacaine™ is SkyePharma's novel sustained-release
injectable formulation of the local anaesthetic bupivacaine, currently widely
used as a local or regional anaesthetic during surgery, either in a hospital
in-patient setting or in ambulatory (or "day") surgery in which the patient is
discharged from the hospital or clinic shortly after surgery to recover at home.
DepoBupivacaine™ employs SkyePharma's proprietary DepoFoam™ technology and was
shown in Phase I and Phase II studies to provide local relief of pain for more
than 48 hours after a single injection instead of 8-12 hours for conventional
immediate-release bupivacaine. Superior control of pain after discharge is
expected to reduce the need for other analgesics and to improve patient recovery
and rehabilitation. The Phase III trial programme is expected to commence in the
first half of 2006.
We have extended our relationship with Mundipharma, our European marketing
partner for DepoCyte , by granting rights outside North America and Japan for
DepoBupivacaineTM. Under the terms of the agreement we could receive up to $80
million in milestone payments and a 35% share of sales (30% in markets outside
Europe). The milestone payments include a contribution of up to $20 million
towards the cost of the Phase III trial once Mundipharma agrees to the design of
the trial.
DepoBupivacaine™ has also been licensed to the Japanese pharmaceutical company
Maruho for the Japanese market. Maruho will pay SkyePharma up to $18 million in
milestone payments and conduct at its own cost the clinical development of
DepoBupivacaine™ required for regulatory approval in Japan. Additionally,
SkyePharma will receive a share of Maruho's sales in Japan, out of which
SkyePharma will bear the cost of manufacture.
Endo Pharmaceuticals, our North American partner for DepoDur™, which had a right
of first negotiation for commercial rights to DepoBupivacaineTM for North
America, has now relinquished this right, thereby providing a buyer of the
injectables business with unencumbered US rights to this product. Subject the
terms of this sale, we may seek to retain an economic interest in the sales of
DepoBupivacaineTM, which we believe has major commercial potential.
DepoCyt
DepoCyt is an oncology drug for the treatment of lymphomatous meningitis. It
consists of cytarabine in our proprietary DepoFoam™ formulation to avoid the
need for frequent intrathecal (spinal) injections. Sales of DepoCyt in the USA
in 2005 by our partner Enzon were $8 million, up 26% on the prior year. Our
European partner Mundipharma, which launched the product as DepoCyte in February
2004, had sales of $6 million (against $1.5 million in 2004) and is forecasting
a further substantial increase in 2006. We have completed the Phase IV trial
required by the FDA when granting approval for this product and will be
submitting the results to the FDA shortly. We have also filed in Europe for the
additional indication of the most common form of neoplastic meningitis,
associated with solid tumours. A response is expected in mid-2006.
DepoDur™
In December 2004 our US marketing partner Endo Pharmaceuticals launched
DepoDur™, our sustained-release injectable version of the analgesic morphine for
the treatment of post-operative pain. Sales in 2005 were $4 million, which was a
disappointment both to us and to Endo. The product is still in the launch phase
but has now been accepted on more than 400 hospital formularies, the first
gateway to routine hospital use. Given the length of time typically needed to
establish hospital products, we are confident that this initial sales level does
not reflect the full potential of the product.
In the UK, we were informed last year by the UK regulatory agency, the CSM, that
it would recommend approval for DepoDur™, subject to certain conditions being
satisfied. We have been in discussions with the CSM about these conditions
(which did not require further clinical trials) and final UK approval is
expected shortly. This will be used as the basis for seeking approval throughout
the European Union under the EU's Mutual Recognition procedure. Zeneus
Pharmaceuticals, SkyePharma's European licensee for DepoDur™, announced on
6 December 2005 that it had reached agreement to be acquired by the US company
Cephalon Inc. SkyePharma has regained the European rights for DepoDur™ and is
now seeking a new sales and distribution partner for the EU and other
territories outside North America.
Propofol IDD-DTM
Propofol IDD-DTM is our novel formulation of propofol, a widely-used injectable
anaesthetic and sedative. Our formulation was designed not to support microbial
growth, a recognised problem with current versions, and to provide uninterrupted
sedation for 24 hours. This product has satisfactorily completed Phase II
trials. We are conducting additional toxicology studies as required by the FDA
to determine the continued viability of the development programme. Pending
resolution of the Phase III trial design, and a further evaluation of the
commercial potential, this project is under strategic review.
The Future
In the immediate future, we will be concentrating on two tasks: the divestment
of our injectables business and securing a marketing and co-development partner
(or partners) for FlutiformTM. Once these tasks have been completed, we will be
able to focus our management and financial resources on the "new SkyePharma",
consisting of our core inhalation and oral product business. We will drive for
sustainable profitability. At the same time, however, we will invest in our
inhalation and oral product pipeline to make sure that we bring forward the
growth drivers of tomorrow. We have a longer term goal of forward integration
into marketing and sales of our own products in selected specialty therapeutic
areas. I believe that this new focus will create exciting opportunities for
SkyePharma and increase investor confidence in our future.
Frank Condella
Chief Executive
FINANCIAL REVIEW
Turnover
The Group's revenues continue to be sensitive to the timing and receipt of
milestone payments and payments received on the signing of new contracts.
Revenues for 2005, at 61.3 million, were 18% below the 75.2 million reported in
2004. This was primarily due to the absence of a licensing transaction on
Flutiform, continuing Paxil CR supply problems and slower overall market
penetration of Triglide and DepoDur by marketing partners, partly offset by an
increase in manufacturing and distribution revenues. In addition the Company
undertook a strategic shift away from licence terms that prioritise upfront
payments on signature towards deal structures with higher royalty rates and
increased milestone payments tied to product revenue targets. Despite the
decline in 2005, revenues have nevertheless increased at a cumulative annual
growth rate of 24% since 1996.
The absence of a licensing agreement on Flutiform had a double negative impact
on SkyePharma in 2005. First, revenues suffered from the absence of the
anticipated milestone payment and of a partner's contribution towards continuing
development costs of Flutiform. Secondly, SkyePharma's R&D costs exceeded budget
expectations because of the need to press ahead with the development programme
without a partner in order to avoid the risk of impairment to the commercial
potential of this key product if development was delayed.
Contract development and licensing revenue decreased 30% to 27.6 million,
compared with 39.4 million in 2004. This was primarily due to the absence of an
anticipated milestone from the licensing of Flutiform and the change in the
structure of our licence agreements described above. Revenues recognised from
milestone payments and payments received on the signing of agreements amounted
to 22.1 million in 2005 compared with 33.4 million in 2004. The 2005 total
included revenues from First Horizon for the US marketing and distribution
rights for Triglide triggered by FDA approval in May 2005 from Mundipharma for
the licensing of DepoBupivacaine for Europe and from Maruho for the licensing of
DepoBupivacaine for Japan. In addition, 5.7 million of revenue was recognised
from GlaxoSmithKline on the phase III clinical trials of Requip (ropinirole),
from AstraZeneca on the phase III clinical trials of Pulmicort HFA and from
Novartis on the phase II clinical trials of QAB 149. Research and development
costs recharged fell by 8% to 5.5 million, compared with 6.0 million in 2004.
This was mainly due to a fall in the costs recharged to Micap plc in respect of
the development of their microencapsulation technology which has now been
completed.
Royalty income decreased by 16% to 21.7 million, compared with 25.9 million in
2004. Royalty income in 2005 derives principally from Paxil CR, Xatral OD,
DepoCyt, Solaraze, DepoDur and Triglide. Although the Company was able to
negotiate an increase in the royalty rate it receives on GlaxoSmithKline's sales
of Paxil CR from 3% to 4% with effect from March 2005 and also received
royalties based on budgeted sales while the product was temporarily off the US
market, royalties were
still negatively impacted by the continuing supply problems experienced by
GlaxoSmithKline. Excluding Paxil CR, royalties for the balance of SkyePharma's
other products grew by 38%. In addition royalty growth was less than anticipated
due to slower overall market penetration of Triglide and DepoDur by marketing
partners during the year.
Manufacturing and distribution revenue increased by 21% to 12.0 million,
compared with 9.9 million, mainly due to higher production of clinical trial
material and launch quantities for Novartis in respect of QAB 149 and Foradil
Certihaler.
Deferred income
During 2005, there was a net reduction in deferred income of 3.5 million under
SkyePharma's revenue recognition policy. The movement in deferred income was:
31 December 31 December
2004 Received * Recognised 2005
m m m m
Contract development and licensing revenue 14.1 24.1 (27.6 ) 10.6
* Includes exchange adjustments
Cost of sales
Cost of sales comprises research and development expenditures, including the
costs of certain clinical trials incurred on behalf of our collaborative
partners; the direct costs of contract manufacturing; direct costs of licensing
arrangements and royalties payable. Cost of sales increased by 4% to 29.2
million in 2005, compared with 28.2 million in 2004. This was mainly due to an
increase in manufacturing and distribution expenses ahead of the approval and
launch of Triglide. The resulting gross profit decreased 32% to 32.1 million,
compared with 47.0 million in 2004.
Expenses
Selling, marketing and distribution expenses increased significantly to 5.9
million, compared with 1.7 million in 2004. This mainly reflected SkyePharma's
contribution towards the initial launch and marketing costs of DepoDur and
Triglide. No further marketing contributions are due in respect of DepoDur and
contributions on Triglide will terminate in 2007. The Company's total costs in
respect of Triglide in 2005 amount to approximately 4.6 million.
Amortisation of intangible assets decreased slightly to 2.1 million, compared
with 2.2 million in 2004.
Other administration expenses before exceptionals were 13.8 million in 2005, 12%
lower than the 15.6 million reported in 2004, reflecting the first full year of
cost savings following the restructuring started in 2004. The exceptional charge
of 21.4 million comprises non-cash impairment charges of 19.4 million and
abortive transaction costs of 2.0 million. Following the Strategic Review and
the Group's decision to focus on its core oral and pulmonary products and to
divest its injectable business, the Group no longer views its collaborations
with Astralis, Vital Living and Micap as strategic and these investments have
therefore been impaired. In addition, as an injectable project, SkyePharma's
entitlement to negotiate for commercial rights for Psoraxine, Astralis' key
product, is being offered with the injectable business interests. The remaining
2.0 million exceptional charge relates to legal and professional fees relating
to an aborted transaction, as outlined in the Chairman's statement. Other
administration expenses including exceptional items increased by 14.9 million to
35.2 million.
SkyePharma's own research and development expenses in the year decreased by 2.0
million to 26.0 million, mainly due to a reduction in expenditure on Pulmicort
HFA, DepoDur and other injectable products, partly off set by an increase in
expenditure on Flutiform and DepoBupivacaine in advance of their commencement of
phase III clinical trials.
The other expense of 0.4 million comprises a 0.7 million loss due to the
movement in the fair value of the Group's investment in GeneMedix plc, partly
off set by a 0.3 million profit on disposal of part of the Group's holding of
Vectura Group plc shares.
Results
The operating loss before exceptional items was 16.1 million, compared with 0.4
million in 2004, due principally to the reduction in revenue and to increased
marketing contributions. The operating loss after exceptionals increased by 34.4
million to 37.5 million, mainly due to the higher exceptional charges and fall
in revenue.
The finance costs of 22.3 million (2004: 23.9 million) mainly comprise notional
interest on the Paul Capital funding liabilities as well as interest on the
convertible bonds. Finance income includes 9.0 million (2004: 6.0 million) in
respect of a change in the estimated future payments to Paul Capital.
The Group's share of the losses of Astralis was 0.8 million for 2005, compared
with 10,000 in 2004.
The retained loss after exceptionals increased by 32.3 million to 50.9 million,
also due to the higher exceptional charges and fall in revenue.
Earnings before interest, tax, depreciation amortisation and exceptionals showed
a loss of 8.5 million in 2005, compared with a profit of 7.8 million in 2004.
The loss per share after exceptionals was 8.1 pence, which compares with 3.0
pence in 2004.
Foreign currency movements did not have a material impact on the results of
operations in 2005 compared with 2004.
Segment information
Segmental information on revenue and operating loss before exceptionals is as
follows:
Year ended Year ended
31 December 2005 31 December 2004
m m
Revenue
Injectable 10.5 25.6
Oral and Inhalation 50.8 49.6
61.3 75.2
Operating loss pre exceptional items
Injectable (18.6 ) (1.4 )
Oral and Inhalation 2.5 1.0
(16.1 ) (0.4 )
Business segment data includes an allocation of corporate costs to each segment.
Balance sheet
The Group balance sheet at 31 December 2005 shows shareholders' equity of 31.9
million (2004: 36.5 million).
In September 2005 the Group raised 34.8 million net of expenses by means of a
rights issue of 125,627,357 new Ordinary Shares on the basis of one new share
for every five held.
In July 2004 the Group exchanged 49.6 million of its convertible bonds due June
2005 for convertible bonds due May 2024, leaving 9.8 million of the 2005 bonds
outstanding. The 49.6 million 2024 convertible bonds were consolidated to form a
single series with the 20 million 2024 bonds issued in May 2004. In 2005 the
Group issued 20 million 8% convertible bonds due June 2025. In June 2005 the
company repaid the 9.8 million balance on the convertible bonds due June 2005.
As a result of these transactions the Group has 69.6 million convertible bonds
due May 2024 and 20 million convertible bonds due June 2025 outstanding as at
31 December 2005. On the balance sheet these are reflected as 63.6 million in
liabilities and 28.4 million in equity.
In addition the Group has Other Borrowings at 31 December 2005 of 44.6 million
due to Paul Capital Royalty Acquisition Fund. Whilst the contractual
arrangements contemplate the payment of royalties to Paul Capital as outlined in
note 8, IAS 39 requires the Company to record a liability equal to the net
present value of the royalties the Company expects to pay Paul Capital over the
term of the agreement.
Financial assets held at fair value comprise a 3.25 million 5% convertible loan
note from GeneMedix plc. This has been recorded at 0.4 million at 31 December
2005, being the lower of cost and net realisable value assuming conversion of
the note into GeneMedix ordinary shares.
Liquidity and capital resources
At 31 December 2005 SkyePharma had cash and short term deposits of 34.3 million
and no bank overdraft, compared with 15.3 million net cash at 31 December 2004.
Bank and other non convertible debt amounted to 9.9 million at 31 December 2005
(2004: 11.1 million), consisting principally of a 6.9 million property mortgage
secured on the assets of Jago (2004: 7.4 million). In addition the Company has
6% convertible bonds due May 2024 of 69.6 million (2004: 69.6 million) and 8%
convertible bonds due June 2025 of 20.0 million (2004: Nil). Net debt (excluding
the Paul Capital funding liabilities) amounted to 39.2 million (2004: 55.6
million).
In 2005 there was a net cash outflow from operating activities of 7.6 million,
compared with 3.7 million in 2004. During the year the Group spent 2.6 million
on property, plant and equipment and expenditure on intangible assets of 2.3
million mainly relates to the purchase of licenses to intellectual property in
the area of pulmonary delivery. The proceeds on disposal of the Group's non
strategic holding of Vectura shares were 1.6 million.
Cash inflows from financing in were 30.6 million (2004: 2.9 million). The Group
raised 34.8 million net of expenses by means of a rights issue of 125,627,357
new Ordinary Shares. During the year the Group issued 20 million 8% convertible
bonds raising 18.8 million net of expenses. In addition the company repaid the
9.8 million balance on the convertible bonds due June 2005.
Borrowings of 7.4 million were repaid in the period (2004: 8.6 million). This
primarily comprises Paul Capital's share of the Company's royalty income.
The Group paid 2.0 million of costs relating to an aborted strategic transaction
during the year.
International Financial Reporting Standards
The financial information for the year ended 31 December 2005 has been prepared
for the first time in accordance with IFRS. In preparing the financial
information certain first-time adoption provisions have been applied. The
Group's accounting policies and adjustments made on the implementation of IFRS
were disclosed in the interim results announcement issued on 28 September 2005
and the IFRS restatement announcement issued on 3 August 2005 and can be found
on the Group's corporate web site (www.skyepharma.com). Since the publication of
these results the Group has changed its interpretation of the application of IAS
39 to the Paul Capital funding liabilities. The restatement resulted in a
decrease in the 2004 net interest expense of 5.2 million and in the liability at
31 December 2004 of 4.3 million.
Forward looking statements
The foregoing discussions contain certain forward looking statements and are
made in reliance on the safe harbour provisions of the US Private Securities
Litigation Act of 1995. Although SkyePharma believes that the expectations
reflected in these forward looking statements are reasonable, it can give no
assurance that these expectations will materialise. Because the expectations are
subject to risks and uncertainties, actual results may vary significantly from
those expressed or implied by the forward looking statements based upon a number
of factors, which are described in SkyePharma's 20-F and other documents on file
with the SEC. Factors that could cause differences between actual results and
those implied by the forward looking statements contained in this Preliminary
Announcement include, without limitation, risks related to the development of
new products, risks related to obtaining and maintaining regulatory approval for
existing, new or expanded indications of existing and new products, risks
related to SkyePharma's ability to manufacture products on a large scale or at
all, risks related to SkyePharma's and its marketing partners' ability to market
products on a large scale to maintain or expand market share in the face of
changes in customer requirements, competition and technological change, risks
related to regulatory compliance, the risk of product liability claims, risks
related to the ownership and use of intellectual property, and risks related to
SkyePharma's ability to manage growth. SkyePharma undertakes no obligation to
revise or update any such forward looking statement to reflect events or
circumstances after the date of this Preliminary Announcement.
Donald Nicholson
Finance Director
CONSOLIDATED INCOME STATEMENT
for the year ended 31 December 2005
Year to 31 December 2005 Year to 31 December 2004
Pre - Exceptional Pre - Exceptional
Exceptional (note 3) Total Exceptional (note 3) Total
Notes m m m m m m
Revenue 2 61.3 - 61.3 75.2 - 75.2
Cost of sales (29.2 ) - (29.2 ) (28.2 ) - (28.2 )
Gross profit 32.1 - 32.1 47.0 - 47.0
Selling, marketing and
distribution expenses (5.9 ) - (5.9 ) (1.7 ) - (1.7 )
Administration expenses
Amortisation of other
intangibles (2.1 ) - (2.1 ) (2.2 ) - (2.2 )
Other administration expenses (13.8 ) (21.4 ) (35.2 ) (15.6 ) (4.7 ) (20.3 )
(15.9 ) (21.4 ) (37.3 ) (17.8 ) (4.7 ) (22.5 )
Research and development
expenses (26.0 ) - (26.0 ) (28.0 ) - (28.0 )
Other expense (0.4 ) - (0.4 ) 0.1 2.0 2.1
Operating loss (16.1 ) (21.4 ) (37.5 ) (0.4 ) (2.7 ) (3.1 )
Finance costs 4 (22.3 ) - (22.3 ) (17.7 ) (6.2 ) (23.9 )
Finance income 4 10.0 - 10.0 8.6 - 8.6
Share of loss in associate 6 (0.8 ) - (0.8 ) - - -
Loss before income tax (29.2 ) (21.4 ) (50.6 ) (9.5 ) (8.9 ) (18.4 )
Income tax expense (0.3 ) - (0.3 ) (0.2 ) - (0.2 )
Loss for the year (29.5 ) (21.4 ) (50.9 ) (9.7 ) (8.9 ) (18.6 )
Basic and diluted earnings per
share 5 (4.7p ) (3.4p ) (8.1p ) (1.6p ) (1.4p ) (3.0p )
|
All results represent continuing activities.
See Notes to the Preliminary Announcement.
CONSOLIDATED BALANCE SHEET
as at 31 December 2005
31 December 31 December
2005 2004
Notes m m
ASSETS
Non-current assets
Goodwill 68.7 68.7
Other intangible assets 26.8 26.7
Property, plant and equipment 37.1 40.9
Investments in associates 6 0.2 14.3
Available for sale financial assets 7 1.6 5.2
134.4 155.8
Current assets
Inventories 3.6 1.5
Trade and other receivables 14.2 18.2
Financial assets at fair value through profit or loss 0.4 1.1
Cash and cash equivalents 34.3 15.3
52.5 36.1
Total Assets 186.9 191.9
LIABILITIES
Current liabilities
Trade and other payables (21.0 ) (20.6 )
Convertible bonds 8,9 - (9.4 )
Other borrowings 8 (14.3 ) (10.7 )
Derivative financial instruments - (0.2 )
Deferred income (7.7 ) (11.8 )
Provisions - (0.3 )
(43.0 ) (53.0 )
Non current liabilities
Convertible bonds 8,9 (63.6 ) (50.4 )
Other borrowings 8 (40.2 ) (45.1 )
Deferred income (2.9 ) (2.3 )
Other non current liabilities (3.4 ) (2.9 )
Provisions (1.9 ) (1.7 )
(112.0 ) (102.4 )
Total Liabilities (155.0 ) (155.4 )
Net Assets 31.9 36.5
SHAREHOLDERS' EQUITY
Share capital 10 76.6 63.4
Share premium 345.6 321.0
Translation reserve (1.2 ) (3.3 )
Fair value reserve 0.2 (0.5 )
Retained losses (427.1 ) (376.5 )
Other reserves 37.8 32.4
Total Shareholders' Equity 31.9 36.5
|
See Notes to the Preliminary Announcement.
CONSOLIDATED CASH FLOW STATEMENT
for the year ended 31 December 2005
Year to Year to
31 December 31 December
2005 2004
Notes m m
Cash flow from operating activities
Cash used in operations (a ) (7.6 ) (3.7 )
Income tax paid (0.3 ) (0.2 )
Net cash used in operating activities (7.9 ) (3.9 )
Cash flows from investing activities
Purchases of property, plant and equipment (2.6 ) (4.4 )
Purchases of intangible assets (2.3 ) (1.4 )
Purchase of shares in associates (0.2 ) -
Purchase of available for sale investments - (2.2 )
Purchase of own shares (0.4 ) -
Proceeds from disposal of available for sale
investments 1.6 2.7
Net cash used in investing activities (3.9 ) (5.3 )
Cash flows from financing activities
Gross proceeds from rights issue 37.7 -
Expenses of rights issue (2.9 ) -
Proceeds from issue of ordinary share capital 0.1 0.3
Proceeds from issue of convertible bonds due
June 2025 20.0 -
Proceeds from issue of convertible bonds due May
2024 - 20.0
Expenses of issue of convertible bonds due June
2025 (1.2 ) -
Expenses of issue and exchange of convertible
bonds due May 2024 - (3.4 )
Repayment of convertible bonds due June 2005 (9.8 ) -
Repayments of borrowings (7.4 ) (8.6 )
Repayment of finance lease principal - (0.2 )
Interest paid (6.7 ) (5.9 )
Interest received 0.8 0.7
Net cash generated from financing activities 30.6 2.9
Effect of exchange rate changes 0.2 (0.4 )
Net increase/ (decrease) in cash and cash
equivalents 19.0 (6.7 )
Cash and cash equivalents at beginning of the
year 15.3 22.0
Cash and cash equivalents at end of the year 34.3 15.3
|
See Notes to the Preliminary Announcement.
NOTES TO THE CONSOLIDATED CASH FLOW STATEMENT
(a) Cash flow from operating activities
Year to
31 December Year to
2005 31 December
m 2004 m
Loss for the year (50.9 ) (18.6 )
Adjustments for:
Tax 0.3 0.2
Depreciation 6.2 6.0
Amortisation 2.1 2.2
Impairments 19.4 3.5
Fair value (gain)/ loss on derivative financial instruments (0.3 ) 0.5
Finance costs 22.3 23.9
Finance income (10.0 ) (6.8 )
Share of loss in associate 0.8 -
Profit on disposal of available for sale financial assets (0.3 ) (2.0 )
Other non-cash changes 3.2 4.0
Operating cash flows before movements in working capital (7.2 ) 12.9
Changes in working capital
Increase in inventories (2.1 ) (0.2 )
Decrease/ (increase) in trade and other receivables 4.2 (5.9 )
Increase in trade and other payables 1.2 4.0
Decrease in deferred income (3.4 ) (13.0 )
Decrease in provisions (0.3 ) (1.5 )
Cash used in operations (7.6 ) (3.7 )
Notes to the Preliminary Announcement
1 Basis of preparation
The unaudited preliminary announcement for the year ended 2005 has been prepared
in accordance with International Financial Reporting Standards (IFRS) as adopted
by the EU. The Group's accounting policies and adjustments made on the
implementation of IFRS were disclosed in the
interim results announcement issued on 28 September 2005 and the IFRS
restatement announcement issued on 3 August 2005 and can be found on the Group's
corporate web site (www.skyepharma.com). Since the publication of these results
the Group has made the following change to the application of IFRS, reflecting
the endorsement by the EU of amended standards and emerging industry practice.
The Group had previously treated the proceeds received from Paul Capital as a
floating rate financial liability in accordance with the guidance in paragraph
AG7 of IAS 39; Financial instruments: Recognition and measurement. This was also
consistent with the treatment under US GAAP. The Group has now concluded that
the Paul Capital funding liabilities should be treated in accordance with the
guidance in paragraph AG8 of IAS 39, not AG7 as previously used. This has the
effect that the estimated payments to Paul Capital are discounted using each
contract's original effective interest and any adjustment is recognised as
income or expense in the income statement. Under the previous accounting (and US
GAAP) such fluctuations were effectively spread forward and reflected in a
reduced implicit interest cost in future years. The restatement resulted in a
decrease in the 2004 net interest expense of 5.2 million and in the liability at
31 December 2004 of 4.3 million. There are no implications for cash flow or
operating loss.
The financial information in this statement does not constitute statutory
accounts within the meaning of Section 240 of the Companies Act 1985. Statutory
accounts for the year ended 31 December 2004, which were prepared under UK GAAP,
have been filed with the Registrar of Companies. The auditors' report on those
accounts was unqualified and did not contain a statement under Section 237 of
the Companies Act 1985.
The Company's working capital requirements continue to be affected by the timing
and receipt of milestone payments and payments received on the signing of new
contracts. The Company's future cash flows will also be impacted by the
Company's change in strategy as outlined in the EGM notice dated 16 February
2006, principally its stated aim of moving to sustainable profitability in the
shortest possible time and its refocus to concentrate on oral and pulmonary
products. Consequently the Group's near term working capital requirements are
uncertain and sensitive to the timing of a number of initiatives required to
provide the financial flexibility to implement the new strategy. These
initiatives include the licensing of Flutiform, the divestment of its injectable
business interests, which is expected to require shareholder approval, and the
delay of certain licensing discussions, such as US licensing for DepoBupivacaine
pending the divestment of its injectables business.
The Directors have reviewed the working capital requirements of the Group for
the next twelve months and have a reasonable expectation that sufficient funds
will be raised from these initiatives and have therefore prepared the financial
information contained herein on a going concern basis which assumes that the
Company will continue in operational existence for the foreseeable future.
Given the above uncertainties the auditors have indicated that their report may
contain a reference to going concern relating to these matters. The financial
information in this announcement does not reflect any adjustments that would be
required to be made if it was to be prepared on a basis other than the going
concern basis.
2 Segment information
Based on the risks and returns of the various segments, the Directors consider
that the Group's primary reporting format is by business segment with
geographical reporting being the secondary format. The Group is a speciality
pharmaceutical company, using its multiple drug delivery technologies to create
a product pipeline for out-licensing to marketing partners. The business
segments consist of the Injectable business and the Oral and Inhalation
business. Business segment data includes an allocation of corporate costs to
each segment on an appropriate basis. There are no material inter-segment
transfers. All Group activities are continuing operations.
Revenue by business segment:
Year ended Year ended
31 December 2005 31 December 2004
m m
Injectable 10.5 25.6
Oral and Inhalation 50.8 49.6
61.3 75.2
Revenue earned can be analysed as:
Contract development and licensing Milestone
payments 22.1 33.4
Research and development costs recharged 5.5 6.0
27.6 39.4
Royalties 21.7 25.9
Manufacturing and distribution 12.0 9.9
61.3 75.2
Operating profit/ (loss) by business segment:
Year ended Year ended
31 December 2005 31 December 2004
m m
Injectable (18.6 ) (1.4 )
Oral and Inhalation 2.5 1.0
Operating loss pre exceptional items (16.1 ) (0.4 )
Exceptional items (21.4 ) (2.7 )
Operating loss (37.5 ) (3.1 )
Share of loss in associate (0.8 ) -
Net interest (12.3 ) (15.3 )
Tax (0.3 ) (0.2 )
Loss after tax (50.9 ) (18.6 )
3 Exceptional items
Year ended Year ended
31 December 2005 31 December 2004
m m
Impairments (19.4 ) (3.5 )
Abortive transaction costs (2.0 ) -
Restructuring costs - (1.2 )
Profit on disposal of available-for-sale
investment - 2.0
Convertible bonds exchange (6.2 )
(21.4 ) (8.9 )
Following the Strategic Review and the Group's decision to focus on its core
oral and pulmonary products and to divest its injectable business, the Group no
longer views its collaborations with Astralis, Vital Living and Micap as
strategic and these investments have therefore been impaired resulting in an
exceptional charge of 19.4 million.
During the year the Group incurred 2.0 million legal and professional fees
relating to an aborted strategic transaction.
4 Finance costs and income
Year ended Year ended
31 December 2005 31 December 2004
m m
Interest and similar expense:
Interest:
- bank borrowings (0.5 ) (0.7 )
- Paul Capital arrangements (12.7 ) (11.3 )
- interest on convertible bonds (5.8 ) (5.7 )
(19.0 ) (17.7 )
Foreign exchange on Paul Capital arrangements (3.3 ) -
Fair value losses on financial instruments:
- loss on exchange of convertible bonds - (6.2 )
Total interest and similar expense (22.3 ) (23.9 )
Interest and similar income:
Paul Capital change in estimated future payments 9.0 6.0
Other interest income 1.0 0.8
Foreign exchange on Paul Capital arrangements - 1.8
Total interest and similar income 10.0 8.6
5 Earnings per share
Year to Year to
31 December 2005 31 December 2004
m m
Attributable loss before exceptional items (29.5 ) (9.7 )
Exceptional items (21.4 ) (8.9 )
Basic and diluted attributable loss (50.9 ) (18.6 )
Number Number
m m
Basic and diluted weighted average number of
shares in issue 624.9 615.2
Loss per Ordinary Share before exceptional
items (4.7p ) (1.6p )
Exceptional items (3.4p ) (1.4p )
Basic and diluted loss per Ordinary Share (8.1p ) (3.0p )
There is no difference between basic and diluted loss per share since in a loss
making year all potential shares from convertible bonds, stock options, warrants
and contingent issuance of shares are anti dilutive.
Shares held by the SkyePharma PLC General Employee Benefit Trust have been
excluded from the weighted average number of shares.
6 Investments in associates
As at As at
31 December 2005 31 December 2004
m m
Beginning of the year 14.3 -
Reclassification of investment as associate - 14.2
Additions 3.0 0.1
Share of loss (0.8 ) -
Impairment (16.3 ) -
End of the year 0.2 14.3
The investment in Astralis Limited was recorded at 0.2 million at 31 December
2005 (2004: 14.3 million) and had a market value of 0.4 million (2004: 9.6
million). Following the Strategic Review and the Group's decision to focus on
its core oral and pulmonary products and to divest its injectable business, the
Group no longer views its collaboration with Astralis as strategic. This
combined with the current uncertainties concerning Astralis' financial position
resulted in the Group impairing its investment to its estimated fair value.
7 Available for sale financial assets
As at As at
31 December 2005 31 December 2004
m m
Beginning of the year 5.2 22.0
Exchange 0.1 -
Reclassification as associate - (14.2 )
Additions 0.1 2.0
Disposal (1.8 ) (0.6 )
Impairments (2.6 ) (3.5 )
Revaluation surplus/ (deficit) transfer 0.6 (0.5 )
End of the year 1.6 5.2
Available for sale financial assets comprise the following unlisted securities:
Vectura Group plc
During 2005 the Group sold 2 million ordinary shares in Vectura for 1.6 million.
As at 31 December 2005 the remaining holding was 1.2 million ordinary shares.
The investment was recorded at 1.0 million at 31 December 2005 (2004: 2.0
million). In January 2006 the Group sold the remaining 1.2 million ordinary
shares.
Vital Living Inc
The investment in Vital Living was recorded at 0.4 million at 31 December 2005
(2004: 1.7 million). Following the Strategic Review and the Group's decision to
focus on its core oral and pulmonary products and to divest its injectable
business, the Group no longer views its collaboration with Vital Living as
strategic and this investment has therefore been impaired.
Micap plc
The investment in Micap recorded at 0.2 million at 31 December 2005 (2004: 1.5
million). Following the Strategic Review and the Group's decision to focus on
its core oral and pulmonary products and to divest its injectable business, the
Group no longer views its collaboration with Micap as strategic and this
investment has therefore been impaired.
8 Borrowings
As at As at
31 December 2005 31 December 2004
m m
Current
Convertible bonds due June 2005 - 9.4
Bank borrowings 2.3 3.5
Property mortgage 0.3 0.3
Paul Capital funding liabilities 11.6 6.8
Finance lease liabilities 0.1 0.1
Other current borrowings 14.3 10.7
Total current borrowings 14.3 20.1
Non-current
Convertible bonds due May 2024 50.8 50.4
Convertible bonds due June 2025 12.8 -
63.6 50.4
Bank borrowings 0.6 -
Property mortgage 6.6 7.1
Paul Capital funding liabilities 33.0 37.9
Finance lease liabilities - 0.1
Other non-current borrowings 40.2 45.1
Total non-current borrowings 103.8 95.5
Total borrowings 118.1 115.6
Bank Borrowings
At 31 December 2005 bank borrowings include two amounts due to the
Basellandschaftliche Kantonalbank of 0.9 million (CHF 2 million) and 0.7 million
(CHF 1.5 million) (2004: 0.9 million (CHF 2 million) and 0.7 million (CHF 1.5
million)). Both loans can be terminated with six weeks notice by either party
and bear interest at 6.5% and 6.0% respectively. Both loans are secured on the
assets of Jago and the 0.7 million (CHF 1.5 million) loan is guaranteed by
SkyePharma PLC.
The Group had a loan as at 31 December 2005 with GE Capital Corp of 1.4 million
($2.4 million) (2004: 1.9 million ($3.7 million)). The loan is secured by
certain assets of SkyePharma Inc, SkyePharma US Inc and SkyePharma PLC. The loan
bears interest at 8.0% and is repayable by installments until September 2007.
Property Mortgage
At 31 December 2005, the Group had a property mortgage facility with the
Basellandschaftliche Kantonalbank of 6.9 million (CHF 15.5 million) (2004: 7.4
million (CHF 16.1 million)). The mortgage is in two tranches, both secured by
the assets of Jago. The first tranche of 2.7 million (CHF 6.2 million) bears
interest at 2.75% and is repayable by installments over 20 years semi-annually.
The second tranche of 4.1 million (CHF 9.3 million) bears interest at 2.75% and
is repayable by installments over 50 years semi-annually.
Paul Capital Funding Liabilities
The Group entered into two transactions with Paul Capital Royalty Acquisition
Fund ('Paul Capital') in 2000 and 2002. Under these transactions Paul Capital
provided a total of $60 million in return for the sale of a portion of the
potential future royalty and revenue streams on a selection of the Group's
products.
Whilst the contractual arrangement with Paul Capital is a royalty agreement
under which royalties are payable on revenues earned and payments received, the
proceeds received from Paul Capital meet the definition of a financial liability
under IAS 39, and are treated as a financial liability. Royalties paid to Paul
Capital are treated as repayment of the liability and notional interest is
charged on the liability. The estimated future payments to Paul Capital are
discounted using each contract's original effective interest and any adjustment
is recognised as income or expense in the income statement.
9 Convertible Bonds
In June 2005 the Group issued 20 million 8% convertible bonds, with a first put
after five years by the holder of the bonds, and a final maturity of June 2025.
The bonds are convertible at the option of the holder into SkyePharma Ordinary
Shares at an initial conversion price of 77 pence at any time prior to maturity.
The bond contains a price reset feature such that if on 3 June 2006 the
Company's average share price for the preceding 10 days (reset price) is less
than the conversion price, then the conversion price shall be adjusted to the
reset price subject to a maximum reduction of 25% in the conversion price.
Unless previously redeemed or converted, the bonds will be redeemed by the Group
at their principal amount in June 2025. The convertible bonds existing at
31 December 2005, due in May 2024, were not affected by this transaction.
On 19 June 2005 9.8 million of convertible bonds due June 2005 were redeemed in
full by the Company at their principal amount.
As a result of these transactions the Group has 69.6 million convertible bonds
due May 2024 at a conversion price of 95 pence, and 20 million convertible bonds
due June 2025 at a conversion price of 77 pence.
10 Share capital
Ordinary Deferred 'B'
Shares of 10p Shares of 10p Total nominal
each Nominal value each Nominal value value
Number m Number m m
At 1 January 2004 618,669,940 61.9 12,000,000 1.2 63.1
Exercise of share options 478,803 - - - -
Issue of shares to
Research Development
Foundation 3,250,000 0.3 - - 0.3
At 1 January 2005 622,398,743 62.2 12,000,000 1.2 63.4
Rights issue 125,627,357 12.6 - - 12.6
Acquisition of shares in
Astralis 5,482,238 0.6 - - 0.6
Exercise of share options 255,808 - - - -
At 31 December 2005 753,764,146 75.4 12,000,000 1.2 76.6
The Group raised 34.8 million net of expenses by means of a rights issue of
125,627,357 new ordinary shares.
The Group also issued 5,482,238 Ordinary Shares to two former Astralis Directors
to acquire 11,160,000 common shares in Astralis.
About SkyePharma
SkyePharma PLC develops pharmaceutical products benefiting from world-leading
drug delivery technologies that provide easier-to-use and more effective drug
formulations. There are now twelve approved products incorporating SkyePharma's
technologies in the areas of oral, injectable, inhaled and topical delivery,
supported by advanced solubilisation capabilities. For more information, visit
http://www.skyepharma.com/.